| A224 |
H2L6 Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
|
|
| A225 |
M1295 Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
|
|
| A226 |
Eblasakimab Biosimilar（Anti-IL-13Ra1 / CD213a1 Reference Antibody）
Featured
|
|
|
| A227 |
Wake Forest U. patent anti-IL-13RA2 Biosimilar（Anti-IL-13Ra2 / CD213a2 Reference Antibody）
Featured
|
|
|
| A228 |
Ordesekimab Biosimilar（Anti-IL-15 Reference Antibody）
Featured
|
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD). |
.png)
|
| A229 |
DISC0280 Biosimilar（Anti-IL-15 Reference Antibody）
Featured
|
|
|
| A230 |
Brodalumab Biosimilar（Anti-IL-17Ra / CD217 Reference Antibody）
Featured
|
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis. |
|
| A231 |
GSK 1070806 Biosimilar（Anti-IL-18 Reference Antibody）
Featured
|
|
|
| A232 |
ABT-325 Biosimilar（Anti-IL-18 Reference Antibody）
Featured
|
|
|
| A233 |
Gevokizumab Biosimilar（Anti-IL-1b Reference Antibody）
Featured
|
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II). |
.png)
|
| A234 |
CDP484 Biosimilar（Anti-IL-1b Reference Antibody）
Featured
|
|
|
| A235 |
Canakinumab Biosimilar（Anti-IL-1b Reference Antibody）
Featured
|
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin. |
.png)
|
| A236 |
AMG 108 Biosimilar（Anti-IL-1R1 / CD121a Reference Antibody）
Featured
|
|
|
| A237 |
Nidanilimab Biosimilar（Anti-IL-1RAP / IL-1R3 Reference Antibody）
Featured
|
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) . |
.png)
|
| A238 |
Melrilimab Biosimilar（Anti-IL-1RL1 / ST2 / IL-33R Reference Antibody）
Featured
|
Melrilimab (GSK 3772847) is an IgG2-kappa anti-IL1RL1/ST2/IL33R/DER4/FIT-1 monoclonal antibody. Melrilimab can be used for the research of asthma. |
.png)
|
| A239 |
Astegolimab Biosimilar（Anti-IL-1RL1 / ST2 / IL-33R Reference Antibody）
Featured
|
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. Astegolimab has the potential for chronic obstructive pulmonary disease (COPD) research. |
.png)
|
| A240 |
Imsidolimab Biosimilar（Anti-IL-1RL2 / IL-36R Reference Antibody）
Featured
|
Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases. |
.png)
|
| A241 |
Fletikumab Biosimilar（Anti-IL-20 Reference Antibody）
Featured
|
Fletikumab (NNC0109-0012) is a monoclonal antibody targeting to IL-20. Fletikumab can be used for inflammation research, such as rheumatoid arthritis. |
.png)
|
| A242 |
Cheng Kung U. patent anti-IL-20 Biosimilar（Anti-IL-20 Reference Antibody）
Featured
|
|
|
| A243 |
Cheng Kung U. patent anti-IL-20R1 Biosimilar（Anti-IL-20Ra Reference Antibody）
Featured
|
|
|
| A244 |
Avizakimab Biosimilar（Anti-IL-21 Reference Antibody）
Featured
|
Avizakimab (BOS161721) is a humanized IgG1 monoclonal antibody that targets interleukin-21. |
.png)
|
| A245 |
Lilly patent anti-IL-21 Biosimilar（Anti-IL-21 Reference Antibody）
Featured
|
|
|
| A246 |
Fezakinumab Biosimilar（Anti-IL-22 Reference Antibody）
Featured
|
Fezakinumab is an interleukin-22 (IL-22) monoclonal antibody. Fezakinumab can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis. |
.png)
|
| A247 |
ARGX-112 Biosimilar（Anti-IL-22Ra Reference Antibody）
Featured
|
|
|
| A248 |
Guselkumab Biosimilar（Anti-IL-23 Reference Antibody）
Featured
|
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research. |
.png)
|
| A249 |
Mirikizumab Biosimilar（Anti-IL-23 Reference Antibody）
Featured
|
Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease. |
.png)
|
| A250 |
LY2525623 Biosimilar（Anti-IL-23 Reference Antibody）
Featured
|
|
|
| A251 |
Brazikumab Biosimilar（Anti-IL-23 Reference Antibody）
Featured
|
Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for the research of Crohn's disease. |
.png)
|
| A252 |
Tildrakizumab Biosimilar（Anti-IL-23a Reference Antibody）
Featured
|
Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis. |
.png)
|
| A128 |
Risankizumab Biosimilar（Anti-IL-23a Reference Antibody）
Featured
|
Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis. |
|
